New antibody for lung scarring passes first safety check in healthy volunteers
NCT ID NCT06310746
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a single dose of HLX6018, an experimental antibody, in 66 healthy adults to see if it is safe and how the body handles it. HLX6018 is designed to block a protein pathway involved in idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. Because this is the first human trial, it only looks at safety and drug levels—not whether it actually treats IPF.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HLX6018 (a monoclonal antibody that targets GARP/TGF-β1)
What this could lead to
If this early safety study goes well, it could pave the way for testing HLX6018 as a potential treatment for idiopathic pulmonary fibrosis (IPF), a serious lung disease.
What could go wrong
This is a very early Phase 1 trial in healthy people, not patients. It only checks safety and dosing—not whether the drug works for IPF. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Hospital of Jilin University
Changchun, Jilin, China